# A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery

> **NCT02691026** · PHASE2 · TERMINATED · sponsor: **Oslo University Hospital** · enrollment: 8 (actual)

## Conditions studied

- Malignant Peripheral Nerve Sheath Tumour (MPNST)

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02691026
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Slow enrollment as a result of low incidence of MPNST and the COVID-19 pandemic.
- **Last updated:** 2021-06-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02691026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02691026, "A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02691026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*